Poul Nissen serves as an Adjunct Professor in the Department of Drug Design and Pharmacology within the Faculty of Health and Medical Sciences at the University of Copenhagen. His research spans membrane transport biology and cellular stress response mechanisms, with particular emphasis on P-type ATPases and calcium signaling pathways. His primary research interests include Membrane Transport Biology , Structural Biology of Ion Pumps , and ER Stress-Induced Cell Death Mechanisms . Work on thapsigargin analogs and α-synuclein interactions reveals therapeutic applications in neurodegenerative diseases and cancer. Recent publications demonstrate sustained focus on calcium homeostasis disruptions in pathological conditions. His publication portfolio shows significant impact with 564 citations for the seminal 2011 review on P-Type ATPases, referenced in 4 patents and 2 Wikipedia pages. Additional work has been highlighted by 5 news outlets and discussed across academic platforms including Mendeley (588 readers) and X (21 user posts). Nissen maintains active research collaborations evidenced by co-authorship on recent studies involving plasma membrane calcium pumps and ER stress responses. His laboratory investigations focus on molecular mechanisms linking ion transport dysregulation to disease pathologies, particularly in cancer and neurodegeneration contexts.
Johan Andersen-Ranberg serves as an Assistant Professor in the Department of Plant and Environmental Sciences at the University of Copenhagen's Faculty of Science, specializing in the Section for Plant Biochemistry. His research focuses on developing sustainable production systems using algae, particularly Nannochloropsis oceanica, to create high-value molecules from carbon dioxide. His educational journey includes a PhD from the University of Copenhagen with thesis titled 'Biosynthesis of High Value Bioactive Natural Products,' an MSc in Applied Biotechnology from Uppsala University (thesis: 'Utilizing Synthetic Biology in Cyanobacteria'), and a BSc in Medicine and Technology from the Technical University of Denmark. He completed postdoctoral training at the University of California Berkeley in Prof. Krishna Niyogi's laboratory, characterizing genes involved in pigment biosynthesis in stramenophile algae. Andersen-Ranberg's research interests center on algae biosynthesis for sustainability, with a vision to establish Nannochloropsis oceanica as both an Earth-based sustainable production system and potential agricultural crop for space colonization applications. His work spans genetic engineering of eukaryotic algae, carotenoid biosynthesis, cytochrome P450 enzymes, and commercialization of engineered bioproduction hosts. Current projects include developing gene engineering tools for N. oceanica, studying pigment biosynthesis in eukaryotic algae, and creating production platforms for plant natural compounds used in non-lethal rodent pest control products. His publication record demonstrates consistent high-impact research output with recent articles in Nature Communications, Science Advances, Current Biology, and Trends in Plant Science. The research trends show a progression from fundamental biochemical characterization toward applied bioproduction technologies, with increasing focus on engineering approaches for sustainable manufacturing. His work bridges basic science with commercial applications, particularly in the areas of sustainable production systems that utilize solar energy and carbon dioxide. Andersen-Ranberg maintains active collaborations across international research networks, with external collaborations spanning multiple countries as indicated by his research output metrics. His work has been referenced in policy sources, picked up by numerous news outlets, and cited across various social media platforms including X (formerly Twitter) and Facebook. His research has substantial academic impact with hundreds of Mendeley readers across his publications. His laboratory focuses on developing N. oceanica as a production system, leveraging its unique evolutionary position within the SAR supergroup that is responsible for over 40% of Earth's annual carbon dioxide fixation. The research group works on creating sustainable production platforms suitable for both terrestrial applications and potential use in long-duration space missions, such as Mars colonization efforts.
Changsi Cai is an Associate Professor in the Department of Neuroscience at the University of Copenhagen, where he leads the Cai Lab focused on neurovascular research. His work bridges neural signaling, vascular biology, and neuroengineering. Research Focus: Dr. Cai investigates neurovascular coupling mechanisms with emphasis on aging and neurodegeneration. His lab studies: Calcium dynamics in vascular mural cells Pericyte physiology in capillary regulation Magnetic neuromodulation technologies for neurological disorders Sex differences in Alzheimer's pathophysiology Real-time neurovascular imaging techniques Publication Trends: Recent work (2021-2025) shows consistent focus on: 1) Age-related decline in neurovascular function, 2) Advanced micro-coil neuromodulation systems, 3) Cellular mechanisms of brain capillary perfusion, and 4) Validation of novel Alzheimer's disease models. Laboratory: The Cai Lab develops cutting-edge methods for studying neurovascular interactions, including MEMS-based devices and in vivo imaging platforms.
Pablo Pennisi is an Associate Professor at Aalborg University's Department of Health Science and Technology, Faculty of Medicine. His research bridges engineering and biology, focusing on regenerative medicine, stem cell dynamics, and biomaterial development for tissue repair. He leads multiple EU-funded projects including BONEGEL and STRONG-UR advancing 3D-bioprinting and smart hydrogels. Education: Ph.D. in Biomedical Sciences and Engineering (2004-2008) M.Sc. in Bioelectronics, Centro de Investigación y de Estudios Avanzados del IPN (2001-2002) Bioengineering degree, Universidad Nacional de Entre Ríos (1991-1998) University Pedagogics Certification (2011-2013) Research Focus: Dr. Pennisi investigates how microenvironmental signals regulate stem cell fate, particularly in muscle regeneration. His work utilizes hydrogels, 3D bioprinting, and electrical stimulation to develop novel therapeutic strategies for tissue repair and chronic wound healing. Projects and Funding: BONEGEL: Injectable smart hydrogels for bone defects (Horizon Europe) STRONG-UR: 3D bioprinting for urethral regeneration (Horizon Europe) PULSE: 3D-printed vascular disease models (Danish Foundations) PROMEAT: Cultured meat development (Horizon Europe) Academic Activities: Includes PhD supervision, conference presentations, journal editorship, and membership in research networks like the Cultivated muscle-cell based food (CMBFood) consortium.
Michal Poborsky is a Research Fellow at the Department of Plant and Environmental Sciences within the Faculty of Science at the University of Copenhagen. His work focuses on engineering microbial systems for sustainable production of plant-derived compounds, operating under the Section for Molecular Plant Biology. Education PhD in Biotechnology from University of Copenhagen (awarded July 2022), thesis: Engineering Escherichia coli towards production of plant specialized metabolites His research integrates metabolic engineering, synthetic biology, and enzyme design to optimize microbial cell factories. Key expertise includes cytochrome P450 expression in Escherichia coli , benzylglucosinolate pathway engineering in Saccharomyces cerevisiae , and rational redesign of hydratases for enhanced substrate specificity. His methodologies address critical challenges in heterologous metabolite production, including enzyme functionality, transport engineering, and pathway compartmentalization. Analysis of his 2020-2023 publications reveals a cohesive trajectory in microbial engineering for plant metabolite synthesis. Dominant themes include cytochrome P450 functionality in bacterial systems (2023), comparative pathway engineering in yeast (2022), and precision enzyme engineering for regioselectivity control (2020-2021). These works collectively advance sustainable bioproduction of high-value phytochemicals through innovative strain and pathway design. No scientific awards are documented in the provided materials. While no formal advising roles or grant funding are specified, his collaborative network includes prominent researchers such as Barbara Ann Halkier, Carl Crocoll, and Morten S. Motawie across 5 of his 6 publications. His work has been referenced in 1 patent and garnered significant academic attention with 108 total Mendeley readers. Poborsky operates within the molecular plant biology research group led by Professor Barbara Ann Halkier at Thorvaldsensvej 40, Frederiksberg. His laboratory work centers on microbial strain development, with experimental focus on E. coli and yeast platforms for plant metabolite biosynthesis, leveraging techniques in genetic engineering, enzyme kinetics, and metabolic flux analysis.
Kenneth Thermann Kongstad is an Assistant Professor at the Department of Drug Design and Pharmacology within the Faculty of Health and Medicinal Sciences at the University of Copenhagen. His research spans interdisciplinary projects at the intersection of analytical chemistry, spectroscopy, biochemistry, and pharmacology. He has established an endophyte research lab focused on discovering novel drug leads from microorganisms living within plants, a largely unexplored area in natural product research with significant potential. His work bridges analytical science with pharmacological applications through collaborations with the Pharmacotherapy Research section and other departments. Dr. Kongstad's educational background includes: PhD from the Faculty of Pharmaceutical Sciences at University of Copenhagen, supervised by Prof. Jerzy W. Jaroszewski (deceased) and Dr. Manfred Spraul MSc. Eng. from Technical University of Denmark (DTU), with research conducted at University of Queensland, Australia under Prof. Rob Capon His primary research interests focus on the discovery of future drug leads from endophytic fungi, quantitative analysis of opioids for pharmacokinetic studies, and chemical characterization of bioengineered organisms. Dr. Kongstad specializes in advanced hyphenated NMR techniques ($$\text{HPLC-PDA-HRMS-SPE-NMR}$$) for natural product research and pharmaceutical applications. His work has developed innovative screening methodologies for semi-high-throughput analysis of plant extracts and identification of bioactive metabolites responsible for antifungal activity. He maintains active collaborations with research groups at Department of Plant and Environmental Sciences (KU), Department of Bioengineering and Biomedicine (DTU) and various departments within KU. Analysis of Dr. Kongstad's recent publications reveals a strong focus on applying advanced analytical techniques to identify bioactive compounds with therapeutic potential. His work spans diabetes research (particularly $$\alpha$$-glucosidase inhibitors), cancer research (multidrug resistance reversal), and pain management (opioid pharmacokinetics). A common thread is the integration of sophisticated analytical methodologies with biological activity screening to accelerate drug discovery from natural sources, especially endophytic fungi and plant extracts. Dr. Kongstad has received professional recognition including: Teacher of the Year (2019) He has established significant research collaborations across multiple institutions and has been involved in multiple funded research projects, including the DSF-funded 'FungalFight' project and collaborative efforts to develop cell factories for producing carminic acid. His endophyte research lab serves as a hub for interdisciplinary research, bringing together expertise in natural product chemistry, pharmacology, and analytical science. He has also filed two patents related to cell factory development for carminic acid production. His laboratory focuses on chemical and biological characterization of endophytic fungi, with particular attention to compounds with antifungal, antidiabetic, and other therapeutic properties. The lab integrates advanced analytical techniques with biological screening to identify bioactive metabolites. Dr. Kongstad's team collaborates extensively with researchers specializing in pharmacokinetic modeling, contributing to the development of personalized medicine approaches. He has also maintained editorial roles for journals including Natural Product Research, Analytical Methods, and Journal of Separation Science.
Niels-Ulrik Frigaard is an Associate Professor in the Department of Biology at the University of Copenhagen's Faculty of Science, specializing in Marine Biology. His research laboratory focuses on the ecophysiology and bioengineering of photosynthetic microorganisms including cyanobacteria, microalgae, and anoxygenic phototrophic bacteria. His research interests center on photosynthetic mechanisms, CO 2 metabolism, and metabolic strategies of photosynthetic microbes. Frigaard investigates how these organisms can be utilized for practical applications in CO 2 capture and biosynthesis of metabolites including pigments, sugars, and other compounds. His methodologies integrate genetic and physiological techniques with biochemical and molecular analyses applied to both laboratory cultures and natural/engineered microbial communities. His publication portfolio demonstrates significant contributions to photobiotechnology, with research spanning from fundamental photosynthetic mechanisms to applied biotechnology. Recent work shows increasing focus on carbon capture applications and metabolic engineering of cyanobacteria for bioproduct synthesis. Dr. Frigaard maintains an active research program with substantial scholarly output, as evidenced by numerous high-impact publications and citations across diverse platforms including Scopus, Mendeley, and Wikipedia. His work has been featured in major news outlets and referenced in patents, indicating significant real-world impact. He leads the Frigaard Lab at the University of Copenhagen, which investigates photosynthetic microorganisms through integrated approaches combining genetic manipulation with physiological and biochemical analyses. The lab maintains strong collaborative networks across multiple countries and research domains.
Ulla Mandel is a Guest Researcher at the Department of Cellular and Molecular Medicine within the Faculty of Health and Medical Sciences at the University of Copenhagen. She is affiliated with the Glycomics Program and focuses on the diagnostic and therapeutic applications of monoclonal antibodies in cancer research. Dr. Mandel's research centers on developing monoclonal antibodies (mAbs) to probe the biosynthesis of mucin-type O-glycosylation and truncated cancer O-glycans. Her work has led to the development of cancer-specific mAbs, with one designated 5E5 currently in a phase 1 clinical trial (CAR-T) at UPENN/Tmunity. She has also pioneered a novel cell-based mucin display platform for exploring the immunogenicity of human cancer mucins, which is being used for vaccine development and generating new cancer-specific mAbs. One of these novel antibodies is currently under preclinical evaluation by a pharmaceutical company. Her publication record shows consistent output in high-impact journals spanning structural biology, glycobiology, cancer research, and immunology. The research demonstrates a clear progression from fundamental glycoscience to translational applications, with increasing focus on cancer-specific therapeutic development. Her work on the 5E5 antibody represents a significant milestone in moving from basic research to clinical application. Dr. Mandel's research has attracted substantial attention, with her publications being cited hundreds of times across multiple high-impact journals. Her work has been highlighted by numerous news outlets, shared extensively on social media platforms, and referenced in multiple patent applications, indicating significant translational potential. She maintains active collaborations with international research groups, particularly with Professor Henrik Clausen and other members of the Glycomics Program at the University of Copenhagen. Her research has established important connections between glycobiology and cancer immunology, opening new avenues for diagnostic and therapeutic development.
